Measles outbreak among previously immunized healthcare workers, the netherlands, 2014

Journal of Infectious Diseases

Volumn 214, Issue 12, 2016, Pages 1980-1986

  Hahné, Susan J M ^a   Lochlainn, Laura M Nic ^a,d   Van Burgel, Nathalie D ^b   Kerkhof, Jeroen ^a   Sane, Jussi ^a,d   Yap, Kioe Bing ^c   Van Binnendijk, Rob S ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b HAGA City Hospital   (Netherlands)

^c Municipal Medical and Health Service of The Hague   (Netherlands)

^d EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

Measles; Outbreak; Vaccination; Vaccine failure; Waning immunity

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; CLINICAL ARTICLE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; EPIDEMIC; FEMALE; HEALTH CARE PERSONNEL; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MALE; MEASLES; PLAQUE REDUCTION NEUTRALIZATION; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; SEROLOGY; THROAT CULTURE; VIRAL PHENOMENA AND FUNCTIONS; VIRUS ATTACK RATE; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; ANTIBODY AFFINITY; BLOOD; HOSPITAL; IMMUNOLOGY; NETHERLANDS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; DISEASE OUTBREAKS; FEMALE; HEALTH PERSONNEL; HOSPITALS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; NETHERLANDS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85016034217     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw480     Document Type: Conference Paper

References (32)

1. Plotkin SA, Orenstein WA. Vaccine. Vol 5. Amsterdam: Saunders Elsevier, 2008.
2. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331:1397-402.
3. Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis 2004; 189(suppl 1):S1-3.
4. WHO. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 84:349-60.
5. Perry RT, Murray JS, Gacic-Dobo M, et al. Progress toward regional measles elimination-Worldwide, 2000-2014. MMWR Morb Mortal Wkly Rep 2015; 64:1246-51.
6. van Lier EA OP, Giesbers H, Conyn-van Spaendonck MAE, Drijfhout IH, Zonnenberg-Hoff IF, de Melker HE. Vaccination coverage national immunization program the Netherlands [in Dutch]. Bilthoven, the Netherlands: RIVM (National Institute for Public Health and the Environment), 2014.
7. Ruijs WL, Hautvast JL, van der Velden K, de Vos S, Knippenberg H, Hulscher ME. Religious subgroups influencing vaccination coverage in the Dutch Bible belt: an ecological study. BMC Public Health 2011; 11:102.
8. Knol MJ, Urbanus AT, Swart EM, et al. Large ongoing measles outbreak in a religious community in the Netherlands since May 2013. Euro Surveill 2013; 18: pii=20580.
9. RIVM. Advice: Protection against measles in health care (in Dutch). http://www. rivm. nl/Documenten-en-publicaties/Professioneel-Praktisch/Richtlijnen/ Infectieziekten/LCI-richtlijnen/LCI-richtlijn-Mazelen-morbilli/Download/ Advies-bescherming-tegen-mazelen-in-de-gezondheidszorg. Accessed 14 February 2016.
10. Mollema L, Smits GP, Berbers GA, et al. High risk of a large measles outbreak despite 30 years of measles vaccination in The Netherlands. Epidemiol Infect 2014; 142:1100-8.
11. Dorigo-Zetsma JW, Leverstein-van Hall MA, Vreeswijk J, et al. Immune status of health care workers to measles virus: evaluation of protective titers in four measles IgG EIAs. J Clin Virol 2015; 69:214-8.
12. Mercader S, Garcia P, Bellini WJ. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin Vac Immunol 2012; 19:1810-7.
13. Sowers SB, Rota JS, Hickman CJ, et al. High concentrations of measles neutralizing antibodies and high avidity measles IgG accurately identify measles reinfection cases. Clin Vac Immunol 2016; 23:707-16.
14. Paunio M, Hedman K, Davidkin I, et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect 2000; 124:263-71.
15. ECDC. Measles case definition and classification. http://ecdc. europa. eu/en/ activities/surveillance/euvac/case-definition/pages/measles. aspx. Accessed 14 February 2016.
16. Cohen BJ, Audet S, Andrews N, et al. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007; 26:59-66.
17. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
18. Nic Lochlainn L, Mandal S, de Sousa R, et al. A unique measles B3 cluster in the United Kingdom and the Netherlands linked to air travel and transit at a large international airport, February to April 2014. Euro Surveill 2016; 21:pii=30177.
19. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year followup. J Infect Dis 2008; 197:950-6.
20. Rosen JB, Rota JS, Hickman CJ, et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis 2014; 58:1205-10.
21. Rota JS, Hickman CJ, Sowers SB, Rota PA, Mercader S, Bellini WJ. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. J Infect Dis 2011; 204(suppl 1): S559-63.
22. Hickman CJ, Hyde TB, Sowers SB, et al. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J Infect Dis 2011; 204(suppl 1):S549-58.
23. Tischer A, Andrews N, Kafatos G, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiol Infect 2007; 135:787-97.
24. Lee MS, Nokes DJ, Hsu HM, Lu CF. Protective titres of measles neutralising antibody. J Med Virol 2000; 62:511-7.
25. Tahara M, Ito Y, Brindley MA, et al. Functional and structural characterization of neutralizing epitopes of measles virus hemagglutinin protein. J Virol 2013; 87:666-75.
26. Tahara M, Ohno S, Sakai K, et al. The receptor-binding site of the measles virus hemagglutinin protein itself constitutes a conserved neutralizing epitope. J Virol 2013; 87:3583-6.
27. Klingele M, Hartter HK, Adu F, Ammerlaan W, Ikusika W, Muller CP. Resistance of recent measles virus wild-type isolates to antibody-mediated neutralization by vaccinees with antibody. J Med Virol 2000; 62:91-8.
28. Finsterbusch T, Wolbert A, Deitemeier I, et al. Measles viruses of genotype H1 evade recognition by vaccine-induced neutralizing antibodies targeting the linear haemagglutinin noose epitope. J Gen Virol 2009; 90:2739-45.
29. Kweder H, Ainouze M, Cosby SL, et al. Mutations in the H, F, or M proteins can facilitate resistance of measles virus to neutralizing human anti-MV sera. Adv Virol 2014; 2014:205617.
30. Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. I Infect Dis 2011; 204(suppl 1):S133-48.
31. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis 2012; 206:1542-8.
32. Fiebelkorn AP, Coleman LA, Belongia EA, et al. Measles virus neutralizing antibody response, cell-mediated immunity, and immunoglobulin G antibody avidity before and after receipt of a third dose of measles, mumps, and rubella vaccine in young adults. J Infect Dis 2016; 213:1115-23.